FBXO21

Across TCGA pan-cancer cohorts, FBXO21 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO21 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher FBXO21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO21 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, UCEC, and BLCA are the cancer types where FBXO21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	IV	0.082	0.659	<.001	12	view →
UCEC	DFS	Median	All	0.969	0.828	.023	12	view →
BLCA	OS	Median	III,IV	0.268	0.657	.004	9	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	9	view →
BRCA	OS	Median	All	0.757	0.963	.044	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO21–COAD (OS)

Open the COAD breakdown →